Zealand, Boehringer's weight loss drug meets main gloal in Phase II trial

Zealand Pharma said that its experimental weight-loss drug, developed with partner Boehringer Ingelheim, achieved up to 14.9% weight loss after 46 weeks in a Phase II trial.

The Phase II dose-finding trial met its primary endpoint, the Danish company added.